

# Biosite® Incorporated Announces Collaboration for Cerebrovascular Injury Targets

Monday August 1, 8:00 am ET

## Agreement Signed with Banyan Biomarkers for Potential Development of Novel Targets

SAN DIEGO, Aug. 1 /PRNewswire-FirstCall/ -- Biosite® Incorporated (Nasdaq: [BSTE](#) - [News](#)) today announced it has signed a collaboration agreement to work with Banyan Biomarkers Inc. (Alachua, Fla.) to review proposed cerebrovascular injury targets discovered with Banyan's animal model of cerebral injury.

Under the collaboration, Biosite may select targets that Banyan nominates. Biosite will then make antibodies to those selected targets using the Company's proprietary antibody development process, which combines immunization of mice and phage display to generate highly diverse libraries of Omniconal® antibodies with high affinity and low cross-reactivity. The antibodies will be used to generate assays for the measurement of these targets in blood samples. Validated targets will then be assessed for commercialization potential, with high-value markers or panels of markers added to Biosite's product development process.

"This alliance complements Biosite's capabilities and enables us to access select Banyan targets," said Gunars Valkirs, Biosite senior vice president Discovery. "Collaborations like these are important for Biosite's Discovery program because they provide access to novel markers in areas of strategic focus to Biosite and may lead to potential product opportunities."

The financial terms of the agreement were not disclosed.

### About Banyan Biomarkers

Founded in collaboration with the University of Florida in March 2002 as Daimonion Diagnostics the company was renamed Banyan Biomarkers Inc. in January 2004. Through contractual arrangements with the University of Florida, Banyan investigators capitalize on the world-renowned facilities at the university's Evelyn F. and William McKnight Brain Institute. More information on the Company can be found at <http://www.banyanbio.com>.

### About Biosite Incorporated

Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions.

Biosite's Triage® rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in over 50 international markets. Information on Biosite can be found at <http://www.biosite.com>.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words "will;" "believes;" "should;" "intends;" "anticipates;" "plans;" "expects;" "estimates;" or similar statements are forward-looking statements. Forward

looking statements include statements about the potential benefits of the collaboration and license agreement between Biosite and Banyan Biomarkers, Biosite's ability to generate antibody libraries of selected targets and evaluate the diagnostic utility of the targets, Biosite's ability to develop and commercialize potential products based on selected targets and Biosite's ability to identify markers or panels of markers for its product development pipeline. Risks that should be considered include risks and uncertainties regarding the discovery and product development process generally, risks associated with the introduction of competitive products from companies with greater capital and resources, uncertainties around the proprietary nature of the targets subject to the collaboration, expansion or development of a direct sales effort in domestic and international markets, and risks and expenses associated with litigation, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, regulatory changes, competitive pressures on average selling prices, and the other risks detailed in Biosite's most recent Annual Report on Form 10-K, as amended, and other SEC filings. Biosite disclaims, any intent or obligation to update these forward-looking statements. Copies of Biosite's public disclosure filings are available from its investor relations department.

Biosite®, Triage® and New Dimensions in Diagnosis® are registered trademarks of Biosite Incorporated. The Company's logo is a trademark of Biosite Incorporated.

---

Source: Biosite Incorporated